FDA Approves New Alzheimer's Treatment: Donanemab Slows Cognitive Decline

Indianapolis, Indiana United States of America
Clinical trials show significant cognitive decline slowing effect in early stages of Alzheimer's disease
Cost: $695 per vial before insurance, $12,522 for six months, about $32,000 for a year
Donanemab works by helping the body remove amyloid plaque buildup in the brain
FDA approves donanemab, a monoclonal antibody treatment for early symptomatic Alzheimer's disease
Made by Eli Lilly and sold under the name Kisunla
FDA Approves New Alzheimer's Treatment: Donanemab Slows Cognitive Decline

In a groundbreaking development, the United States Food and Drug Administration (FDA) has approved donanemab, a monoclonal antibody treatment designed to slow the progression of early symptomatic Alzheimer's disease. The drug, made by Indianapolis-based Eli Lilly, works by helping the body remove amyloid plaque buildup in the brain, a hallmark of Alzheimer's disease. Donanemab is not a cure but has shown to significantly slow cognitive decline in early stages of the disease according to clinical trials. The treatment will be sold under the name Kisunla and will cost $695 per vial before insurance, amounting to $12,522 for a six-month course or about $32,000 for a year. This approval marks a significant milestone in the fight against Alzheimer's disease and offers hope to millions of patients and their families worldwide.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

100%

No Doubts Found At Time Of Publication

Sources

87%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’s

The Name Of The NZ Prefix. I PWA NZI.P.Was Dropped. Pam Belluck Tuesday, 02 July 2024 17:38
  • Unique Points
    • Donanemab is a novel class of treatment that can modestly slow cognitive decline in early stages of Alzheimer’s disease.
    • Bev Krol, a participant in the trial for donanemab, began experiencing forgetfulness about six years ago.
  • Accuracy
    • ]The FDA approved Eli Lilly's new drug, donanemab (Kisunla), for Alzheimer's disease on Tuesday.[
    • Donanemab is a novel class of treatment that can modestly slow cognitive decline in early stages of Alzheimer's disease.
    • Donanemab is similar to Leqembi, another approved Alzheimer's drug from Eisai and Biogen.
    • Patients may be able to stop taking donanemab after it clears the target protein, amyloid, reducing cost and inconvenience as well as risk of side effects.
  • Deception (50%)
    The article is deceptive in the way it presents the safety risks of donanemab and its effectiveness. It implies that donanemab has been proven to modestly slow cognitive decline in early stages of Alzheimer's without mentioning any peer-reviewed studies to support this claim. Additionally, it does not disclose that the drug has not yet been peer-reviewed.
    • The drug, donanemab, to be sold under the brand name Kisunla, is the latest in a novel class of treatments that has been greeted with hope, disappointment and skepticism.
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

96%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

FDA approves a new Alzheimer's drug from Eli Lilly

CNBC News Wednesday, 03 July 2024 11:18
  • Unique Points
    • Evan Seigerman, senior research analyst at BMO Capital Markets, discussed the approval on Squawk Box
  • Accuracy
    • The FDA approved Eli Lilly’s new drug, donanemab (Kisunla), for Alzheimer’s disease on Tuesday.
    • Donanemab is a novel class of treatment that can modestly slow cognitive decline in early stages of Alzheimer’s disease.
    • Donanemab is part of a class of Alzheimer’s treatments called anti-amyloid monoclonal antibodies, which target amyloid plaques in the brain.
    • Depending on brain scans, patients may stop taking the drug after as early as six months or continue for up to 18 months.
    • Donanemab is expected to cost $32,000 for 12 months of treatment.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

FDA approves new Alzheimer's treatment, donanemab from Eli Lilly

CBS News Site: https://www.cbsnews.com/articles/about-us/ Alexander Tin Wednesday, 03 July 2024 12:46
  • Unique Points
    • Donanemab is the third addition to a new class of drugs aimed at slowing the brain's decline in patients with early-stage Alzheimer’s disease.
    • ,
  • Accuracy
    • ]The FDA has approved donanemab, a new Alzheimer's treatment from Eli Lilly.[
    • Donanemab is part of a class of Alzheimer's treatments called anti-amyloid monoclonal antibodies, which target amyloid plaques in the brain.
    • Depending on brain scans, patients may stop taking the drug after as early as six months or continue for up to 18 months.
    • In clinical trials, almost half of patients were able to meaningfully clear out amyloid after about a year of taking the drug with no rebound of amyloid plaque in the following year.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    The article contains some instances of appeals to authority and inflammatory rhetoric, but no formal or dichotomous fallacies are present. The author quotes the FDA and Eli Lilly to establish the credibility of their claims about donanemab's approval and effectiveness. Additionally, the author uses descriptive language like 'promising clinical trial results' and 'meaningful results for people with early symptomatic Alzheimer's disease' to express enthusiasm for the new treatment. However, these expressions do not constitute fallacies.
    • ]The FDA previously rebuffed Eli Lilly’s request for accelerated approval last year, citing concerns about its long-term safety data. After Eli Lilly submitted more data to the FDA, the company said it expected the agency would decide on approval by the end of March.[
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease

CNN News Site: In-Depth Reporting and Analysis with Some Financial Conflicts and Sensational Language Jen Christensen Tuesday, 02 July 2024 17:51
  • Unique Points
    • Donanemab works by helping the body remove amyloid plaque buildup in the brain.
    • The treatment costs $695 per vial before insurance, amounting to $12,522 for a six-month course or about $32,000 for a year.
  • Accuracy
    • ]The FDA approved donanemab, a monoclonal antibody from Eli Lilly to slow the progression of early symptomatic Alzheimer’s disease.[
    • Clinical trials showed that donanemab slowed the progression of Alzheimer’s disease and allowed people to live independent lives for longer.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication